Carl C. Crodel
YOU?
Author Swipe
View article: Patient-reportet outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias
Patient-reportet outcomes regarding the use of complementary and alternative medicine (CAM) in BCR::ABL1-negative myeloproliferative neoplasias Open
Introduction: BCR::ABL1-negative myeloproliferative neoplasms are chronic diseases characterized by high symptom burden due to systemic inflammation. Treatment objectives include cytoreduction and alleviation of symptoms. Beside standard t…
View article: ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis Open
Ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor, is the standard of care for symptomatic patients with myelofibrosis (MF). However, ∼70% of patients discontinue ruxolitinib after ∼5 years, a third of whom report suboptimal splenic respon…
View article: Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis
Molecular predictors of venous and arterial thrombotic events in patients with myelofibrosis Open
View article: Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN)
Comparison of recognition of symptom burden in MPN between patient- and physician-reported assessment – an intraindividual analysis by the German Study Group for MPN (GSG-MPN) Open
View article: Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms
Immunofluorescence microscopy on the blood smear identifies patients with myeloproliferative neoplasms Open
View article: P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL) Open
Topic: 16. Myeloproliferative neoplasms - Clinical Background: Nearly 35% of MF pts have severe thrombocytopenia (TCP) with a shortened median overall survival of 7-15 months (mos) (Masarova 2018, 2020). Most pts present with high symptom …
View article: Molecular‐defined clonal evolution in patients with classical myeloproliferative neoplasms
Molecular‐defined clonal evolution in patients with classical myeloproliferative neoplasms Open
Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2 , CALR and MPL genes provided new insights into their pathogenesis. Next‐generation sequencing (NGS)…
View article: Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany
Diagnosis and treatment of MPN in real life: exploratory and retrospective chart review including 960 MPN patients diagnosed with ET or MF in Germany Open
View article: Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN)
Clinicohematologic and molecular response of essential thrombocythemia patients treated with pegylated interferon-α: a multi-center study of the German Study Group-Myeloproliferative Neoplasms (GSG-MPN) Open
View article: Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms
Histone demethylase KDM4C is a functional dependency in JAK2-mutated neoplasms Open
View article: Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma
Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma Open
Conditioning with treosulfan and fludarabine (Treo/Flu) has been proven to be feasible and efficient in several types of malignancies before allogeneic hematopoietic stem cell transplantation (allo-HSCT). Given its favorable reduced toxici…
View article: Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera Open
View article: Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
Correction: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study Open
View article: Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study
Frequency of infections in 948 MPN patients: a prospective multicenter patient-reported pilot study Open
Drug combinations that target critical pathways are a mainstay of cancer care. To improve current approaches to combination treatment of chronic lymphocytic leukemia (CLL) and gain insights into the underlying biology, we studied the effec…
View article: Lesion mapping of stroke-related erectile dysfunction
Lesion mapping of stroke-related erectile dysfunction Open
Acute ischaemic stroke in brain areas contributing to male sexual function may impair erectile function depending on the lesion site. This study intended to determine associations between stroke-related erectile dysfunction and cerebral is…